719 related articles for article (PubMed ID: 19874553)
1. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Soleimani A; Berntsen A; Svane IM; Pedersen AE
Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
3. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
4. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
Berntsen A; Geertsen PF; Svane IM
Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
7. [An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma].
Gao J; Chen M; Peng ML; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):198-201. PubMed ID: 15760555
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell vaccination of patients with metastatic colorectal cancer.
Burgdorf SK
Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
[TBL] [Abstract][Full Text] [Related]
9. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination.
Burgdorf SK; Claesson MH; Nielsen HJ; Rosenberg J
Acta Oncol; 2009; 48(8):1157-64. PubMed ID: 19863224
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
11. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.
Papewalis C; Fassnacht M; Willenberg HS; Domberg J; Fenk R; Rohr UP; Schinner S; Bornstein SR; Scherbaum WA; Schott M
Clin Endocrinol (Oxf); 2006 Aug; 65(2):215-22. PubMed ID: 16886963
[TBL] [Abstract][Full Text] [Related]
14. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
15. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
Svane IM; Pedersen AE; Nikolajsen K; Zocca MB
Vaccine; 2008 Aug; 26(36):4716-24. PubMed ID: 18616968
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-tumor fusion vaccines for renal cell carcinoma.
Avigan D
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6347S-52S. PubMed ID: 15448029
[TBL] [Abstract][Full Text] [Related]
18. [Reduction of immunosuppression and shift to Th1 response by tumor-DC (dendritic cells) fusion vaccine].
Iinuma H; Okinaga K; Fukushima R; Inaba T; Iwasaki K; Arai T; Tamura J; Kumagai H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1640-2. PubMed ID: 15553669
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
[TBL] [Abstract][Full Text] [Related]
20. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]